PHVS - Pharvaris N.V.

11.83
-1.380   -11.665%

Share volume: 20,599
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$13.21
-1.38
-0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-17.16%
1 Month
-20.60%
3 Months
-33.54%
6 Months
-33.95%
1 Year
-48.88%
2 Year
42.19%
Key data
Stock price
$11.83
P/E Ratio 
0.00
DAY RANGE
$11.76 - $13.90
EPS 
N/A
52 WEEK RANGE
$11.76 - $25.50
52 WEEK CHANGE
-$46.88
MARKET CAP 
941.224 M
YIELD 
N/A
SHARES OUTSTANDING 
52.290 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-14-2025
BETA 
1.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$31,624
AVERAGE 30 VOLUME 
$30,511
Company detail
CEO: Berndt A. E. Modig
Region: US
Website: pharvaris.com
Employees: 30
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pharvaris N.V. focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE) The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Recent news
loading